Close

AbbVie (ABBV) Says Upadacitinib (ABT-494) Met All Primary and Ranked Secondary Endpoints in Phase 3 Study in RA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. CMG


Go back to AbbVie (ABBV) Says Upadacitinib (ABT-494) Met All Primary and Ranked Secondary Endpoints in Phase 3 Study in RA
AbbVie (NYSE: ABBV) Delayed: 167.80 --0 (-0%)
Previous Close $167.80    52 Week High $68.12 
Open $167.80    52 Week Low $50.71 
Day High $167.80    P/E 36.40 
Day Low $167.80    EPS $4.61 
Volume 158